A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders
Authors:
Open Access
- 1 July 2021
- journal article
- review article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 48, 49-88
Abstract
No abstract availableKeywords
Funding Information
- Instituto de Salud Carlos III
- Innovative Medicines Initiative
This publication has 307 references indexed in Scilit:
- CYFIP1 Coordinates mRNA Translation and Cytoskeleton Remodeling to Ensure Proper Dendritic Spine FormationNeuron, 2013
- De Novo Gene Disruptions in Children on the Autistic SpectrumNeuron, 2012
- FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and AutismCell, 2011
- Early Brain Overgrowth in Autism Associated With an Increase in Cortical Surface Area Before Age 2 YearsArchives of General Psychiatry, 2011
- Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterizationJournal of Neurodevelopmental Disorders, 2010
- Structural Variation of Chromosomes in Autism Spectrum DisorderThe American Journal of Human Genetics, 2008
- Molecular Cytogenetic Analysis and Resequencing of Contactin Associated Protein-Like 2 in Autism Spectrum DisordersThe American Journal of Human Genetics, 2008
- Linkage, Association, and Gene-Expression Analyses Identify CNTNAP2 as an Autism-Susceptibility GeneThe American Journal of Human Genetics, 2008
- Early Pharmacological Treatment of Autism: A Rationale for Developmental TreatmentBiological Psychiatry, 2007
- Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X SyndromeNeuron, 2005